Career Possibilities Panel & Speed Networking: Commercial, Medical Affairs, Market Access

Check out the other events in this series

Panelist Bios

Sarah Gheuens, M.D., Ph.D. joined Agios in December 2019 and became chief medical officer in September 2021. She previously served as Agios’ head of clinical development for the genetically defined disease programs, as well as the interim head of regulatory affairs. She has been instrumental in completing the pivotal Phase 3 program for pyruvate kinase deficiency and leading simultaneous regulatory submissions to the FDA and EMA in this indication, as well as designing the pivotal programs for thalassemia, sickle cell disease and the pediatric indications. Prior to joining Agios, Dr. Gheuens worked at Biogen, where she held roles of increasing responsibility in safety, medical affairs and clinical development. Her work was critical for the approval of SPINRAZA®. Before joining Biogen, Dr. Gheuens worked at Beth Israel Deaconess Medical Center (BIDMC), taking care of patients with HIV and neurological complications and doing research on progressive multifocal leukoencephalopathy. Dr. Gheuens received her medical degree from the Free University of Brussels (VUB), Belgium, and completed her neurology residency at the University Hospital of the Free University of Brussels, Belgium, followed by an HIV/neurology fellowship at BIDMC, Boston, Mass., USA. She also holds a Ph.D. in Medical Sciences from the University of Antwerp, Belgium, and a Master’s in Medical Sciences from Harvard Medical School.

Kristie Kapinas is a PhD-trained scientist in Biomedical Sciences in endocrinology. After postdoctoral fellowships focusing on stem cell pluripotency and immunology, she transitions to biotech roles in sales and business development in New England. Using her territory and account management experience, combined with her scientific and medical knowledge background, she was able to find her first role as a disease educator and MSL with Vertex Pharmaceuticals with a focus on rare disease. She had additional roles as Global Director of Advocacy and Alliances at a small biotech, and two other Senior MSL roles in Rheumatology, Hepatitis, and vaccines. She since returned to Vertex as the Sr MSL in the Southwest United States.

Eboni D. Chambers, Ph.D., M.P.A. is the Nephrology Regional Medical Director for Horizon Therapeutics. Dr. Chambers joined Horizon in 2021 to develop Nephrology Key Opinion Leaders through the implementation of clinical and educational strategies in support of Horizon-sponsored trials and educational initiatives. In her short time with the company, her efforts have significantly expanded the presence of Medical Affairs in the Mid- Atlantic region. Prior to this role, Dr. Chambers was a Strategic Account Associate at Precision Medicine Group where she was instrumental in the development of Field Medical Strategy for small molecules and biologics through all phases of the product life cycle within rheumatology, immunology, and rare disease indications. Dr. Chambers is passionate about communicating medical and scientific advances, developing medical strategy, and addressing unmet needs for patient populations. In 2018, Eboni received both her Ph.D. in Pathobiology and M.P.A. in Public Affairs from Brown University- the first-ever dual Pathobiology Ph.D., M.P.A. degree awarded from the University. Her cross-disciplinary background in biomedical science, health economics, and public affairs has been influential in her approach to solve complex problems that impact underserved patient populations.

Tweet It